Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2019.60.431
Efficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model
Yeliz Akgun
; Department of Internal Medicine School of Medicine, Canakkale Onsekiz Mart University, Canakkale Turkey
Serkan Bakirdogen
; Department of Nephrology School of Medicine CanakkaleOnsekiz Mart University, Canakkale,Turkey
Meral Gulay Kadioglu Kocak
; Department of Nephrology Ministry of Health, OkmeydaniEducating and Research Hospital, Istanbul, Turkey
Sibel Bektas
; Department of Pathology Health Sciences University Schoolof Medicine, GaziosmanpasaEducating and Research Hospital Istanbul, Turkey
Ceren Demir
; Department of Internal Medicine School of Medicine, Canakkale Onsekiz Mart University, Canakkale Turkey
Erdem Akbal
; Department of Gastroenterology Bilim University School of Medicine, Istanbul, Turkey
Sait Elmas
; Experimental Medicine and Research Center, Canakkale OnsekizMart University Canakkale, Turkey
Sažetak
Aim To investigate the efficacy of adalimumab treatment
in an experimental rat sclerosing encapsulated peritonitis
(SEP) model.
Methods The study involved 40 Wistar albino rats divided
into four groups: chlorhexidine (CH) group, control
group, CH + adalimumab group, and CH + resting group.
The control group received normal saline intraperitoneally
(i.p.). Other groups received 0.1% CH gluconate, 15% ethanol,
and normal saline mixture i.p. for three weeks in order
to induce SEP. CH + adalimumab group received 5 mg/kg
adalimumab i.p. at the beginning of week 4 and week 6,
while CH + resting group was followed-up for three weeks
without applying any procedure after the onset of SEP. Rats
in groups CH and control group were sacrificed on day 21,
and rats in group CH + adalimumab and CH + resting were
sacrificed on day 42. All groups were evaluated for peritoneal
thickness, inflammation, vascularization, and fibrosis.
Results CH + adalimumab group showed a significant decrease
in peritoneal thickness, fibrosis score, and vascular
score compared with CH group and CH + resting group.
Conclusion Adalimumab can prevent SEP development.
Ključne riječi
Hrčak ID:
240107
URI
Datum izdavanja:
15.10.2019.
Posjeta: 646 *